Brief: Changwei System Technology Receives Approval From Board To Explore Strategic Alternatives
03/03/2022 13:03
March 3 (Reuters) - AnPac Bio-Medical Science Co Ltd
ANPC.O :
* ANPAC BIO’S BIO-CHIP SUBSIDIARY, CHANGWEI SYSTEM
TECHNOLOGY CO.,
LTD., RECEIVES INDEPENDENT VALUATION AND APPROVAL FROM THE BOARD
TO EXPLORE STRATEGIC ALTERNATIVES
* ANPAC BIO-MEDICAL SCIENCE CO LTD- CHINA ALLIANCE
APPRAISAL, CO.,
LTD. PROVIDED CERTIFIED WRITTEN APPRAISAL REPORT WHICH VALUED
CHANGWEI AT RMB 578 MILLION
Source text for Eikon: ID:nGNX3gCf8z
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022